Adam Sragovicz - Conduit Pharmaceuticals Chief Officer
| CDTTW Stock | 0.01 0.00 0.00% |
Executive
Adam Sragovicz is Chief Officer of Conduit Pharmaceuticals
| Age | 54 |
| Address | 4995 Murphy Canyon Road, San Diego, CA, United States, 92123 |
| Phone | 760 471 8536 |
| Web | https://www.conduitpharma.com |
Adam Sragovicz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Sragovicz against Conduit Pharmaceuticals stock is an integral part of due diligence when investing in Conduit Pharmaceuticals. Adam Sragovicz insider activity provides valuable insight into whether Conduit Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Conduit Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Conduit Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Sragovicz over six months ago Acquisition by Adam Sragovicz of 600 shares of Intellicheck Mobilisa at 2.03 subject to Rule 16b-3 | ||
Adam Sragovicz over a year ago Acquisition by Adam Sragovicz of 6494 shares of Presidio Property subject to Rule 16b-3 |
Conduit Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.088) % which means that it has lost $1.088 on every $100 spent on assets. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Conduit Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to climb to 0.06 in 2025, whereas Return On Capital Employed is likely to drop 0.1 in 2025. At this time, Conduit Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 2.2 B in 2025, whereas Intangibles To Total Assets are likely to drop 0.35 in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yoshio Nagai | ioneer Ltd American | 63 | |
| Michael Psihogios | Western Copper and | N/A | |
| Lois Wark | Barrick Gold Corp | 69 | |
| Rousseau Jooste | Barrick Gold Corp | N/A | |
| Sherry Siu | East Africa Metals | 55 | |
| Elena BE | Western Copper and | N/A | |
| Julie Pelly | Western Copper and | N/A | |
| Ken Coon | ioneer Ltd American | 64 | |
| Rodney Quick | Barrick Gold Corp | 48 | |
| John Steele | Barrick Gold Corp | 59 | |
| Jonathan Clegg | Western Copper and | N/A | |
| Poupak Bahamin | Barrick Gold Corp | 54 | |
| Grant Beringer | Barrick Gold Corp | 43 | |
| Sandeep MBA | Western Copper and | 43 | |
| Shena BA | Western Copper and | N/A | |
| Sebastiaan Bock | Barrick Gold Corp | 46 | |
| Matt Weaver | ioneer Ltd American | 59 | |
| Chad Yeftich | ioneer Ltd American | N/A | |
Management Performance
| Return On Asset | -1.09 |
Conduit Pharmaceuticals Leadership Team
Elected by the shareholders, the Conduit Pharmaceuticals' board of directors comprises two types of representatives: Conduit Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Conduit. The board's role is to monitor Conduit Pharmaceuticals' management team and ensure that shareholders' interests are well served. Conduit Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Conduit Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tapolczay, CEO Director | ||
| James Bligh, Interim Director | ||
| Adam Sragovicz, Chief Officer | ||
| Joanne Holland, Chief Officer | ||
| Bill Begien, Senior Relations |
Conduit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Conduit Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.09 | ||||
| Number Of Shares Shorted | 1.35 K | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B | ||||
| Book Value Per Share | (9.50) X | ||||
| Cash Flow From Operations | 344.8 M | ||||
| Beta | 2.27 | ||||
| Total Asset | 3.26 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.